Nervosave Therapeutics
The future of nerve health

Healthy nerves.
Brighter lives.

Protecting, restoring and enhancing nerve function through targeted innovation in nerve health — for people and companion animals.

Scientific visualization of peripheral nerve signallingNERVE HEALTH · INNOVATION · PERFORMANCE
Illustration of perineural AAV9 delivery near a peripheral nerve and Schwann cells
Our approach

Target the nerve.
Think long term.

Our investigational platform uses local perineural administration of AAV vectors to target cells associated with peripheral nerves. The approach is designed to limit systemic exposure and support sustained local therapeutic activity.

LocalPerineural administration
SingleInjection-based delivery approach
Long-term benefitDesigned for sustained local activity
AAV9Investigational vector platform
Our global presence

Built in Europe.
Accelerated in China.

Nervosave Therapeutics is a France-based biotechnology company developing innovative approaches to peripheral nerve health. Through its Chinese subsidiary, Hangzhou Shensui Biotechnology, the group connects European scientific expertise with China’s translational and clinical development ecosystem.

France · Montpellier

Nervosave Therapeutics

Parent company · Research, intellectual property and international strategy.

China · Hangzhou

Hangzhou Shensui Biotechnology

Chinese subsidiary · Translational development, clinical partnerships and operations in China.

杭州神髓生物科技有限公司

One platform. Two innovation ecosystems. Global ambitions.

About our group →
Partnerships

Help shape the next generation of nerve care.

We welcome clinical, scientific, veterinary and investment partners interested in developing this platform.

Get in touch ↗